Skip to content
⚠ KILLER HEALTH · PREVENTATIVE & REGENERATIVE · EDUCATION, PROTOCOLS, PRODUCT · NOT MEDICAL ADVICE · DEATH OPTIONAL ⚠   ⚠ KILLER HEALTH · PREVENTATIVE & REGENERATIVE · EDUCATION, PROTOCOLS, PRODUCT · NOT MEDICAL ADVICE · DEATH OPTIONAL ⚠   ⚠ KILLER HEALTH · PREVENTATIVE & REGENERATIVE · EDUCATION, PROTOCOLS, PRODUCT · NOT MEDICAL ADVICE · DEATH OPTIONAL ⚠   ⚠ KILLER HEALTH · PREVENTATIVE & REGENERATIVE · EDUCATION, PROTOCOLS, PRODUCT · NOT MEDICAL ADVICE · DEATH OPTIONAL ⚠   
KKILLER*.HEALTH

/ Kills / LIBIDO KILL

#06 / DEAD DRIVEINTERMEDIATE🔒 CLINICIAN · NPI-GATEDAS NEEDED

LIBIDO KILL

Kill dead libido. Not your marriage.

// 01

Summary.

Central-pathway sexual-function protocol. Unlike PDE5 inhibitors, these act on desire rather than plumbing. Clinician-gated — hormone panels come first, always.

Before any of this: get a morning total and free testosterone, SHBG, estradiol, prolactin, TSH and a fasting glucose. Low drive is a symptom. Most of the time the lab explains it.

// 02

The stack.

Peptide · 01

PT-141

Bremelanotide · melanocortin agonist

Central desire pathway. Not vascular.

10 mg / vial

Peptide · 02

KISSPEPTIN-10

Upstream GnRH signalling

Acts above the hypothalamic-pituitary axis.

5 mg / vial

Peptide · 03

OXYTOCIN

Neuropeptide

Bonding, arousal and post-orgasmic state.

nasal / SubQ

// 03

Reconstitution.

Dosing for this protocol is prescriber-managed.
PT-141 in particular causes nausea and blood-pressure changes
at doses people commonly self-select.

We publish the framework, the lab work-up and the
registry outcomes — not a self-dosing card.
Ask your clinician.

// 04

Dosing table.

LevelStackUnits (U-100)Freq
CLINICIANPT-141prescriber-setAs needed
CLINICIANKISSPEPTIN-10prescriber-setProtocol-dependent
CLINICIANOXYTOCINprescriber-setAs needed

// 05

Cycle & timing.

WORK-UP

FIRST

Full hormone panel before anything. Low drive is a symptom, not a diagnosis.

AS NEEDED

EPISODIC

This is not a daily protocol. Episodic use, prescriber-managed.

// 06

Contraindications.

  • Uncontrolled hypertension — PT-141 raises blood pressure transiently.
  • Cardiovascular disease without clearance.
  • Pregnancy / lactation.
  • Untreated hypogonadism — treat the cause first.
  • This lane requires a prescriber. Do not self-source.

// 07

Evidence.

CLINICAL

Bremelanotide (PT-141) has an FDA-approved indication for hypoactive sexual desire disorder in premenopausal women. Everything else here is off-label or investigational.

KISSPEPTIN

Human data is early and mostly academic. Promising mechanism, thin outcome literature.

FIRST

The highest-yield intervention in this category is a hormone panel and honest sleep, not a peptide.

// 09

Adverse events.

MILD

0

MODERATE

0

SEVERE

0

Open AE form →

// 10

Related kills.

// Disclaimer

Nothing on killer.health is medical advice. This platform is a research registry and information aggregator. Content is drawn from peer-reviewed publications, clinical protocols and community sources. killer.health does not endorse any compound, supplier or treatment. Always work with a licensed physician inside an established clinical relationship before starting, stopping or modifying any protocol. Data capture is governed by IRB PPRN-001-2025. Anonymous submissions are the default.

// Shop the portfolio · our brands

BUY THE STACK.

Every brand below is ours. Clinician-gated injectables, OTC orals, the book, the lab. One ecosystem, one customer, one login.

Each brand above is a separate operating company under Killer Health. Clinician-gated products require a verified NPI. Peptides are research compounds — most are not FDA-approved for human use and legality varies by jurisdiction. Nothing on this page is medical advice.